News

Chronic psychological stress can help tumors evade immune attack through a chain of molecular events involving gut bacteria and viruses within those bacteria, according to a study led by Weill Cornell Medicine investigators.

Awards, honors and achievements for the month of June.

Over the last two decades, the Weill Cornell Community Clinic has become a bedrock of care for uninsured New Yorkers while also evolving into a deeply embedded part of medical education at Weill Cornell Medical College. 

A recent paper examines the academic, economic and organizational forces jeopardizing a career as a physician-scientist and proposes a framework with the potential to both remedy and revitalize this unique workforce.

Loss of GATA6—a transcription factor that controls which genes are turned on or off—can reprogram colorectal cancer cells into more primitive, adaptable states that can then spread to the liver and establish new tumors, according to Weill Cornell Medicine and Massachusetts Institute of Technology (MIT) researchers.

A new gene therapy appears to be safe in patients diagnosed with Friedreich ataxia cardiomyopathy, a progressive and fatal inherited cardiac disease, according to a phase 1 clinical trial led by Weill Cornell Medicine researchers. 

Dr. Gunisha Kaur has been appointed to the U.S. Commission on International Religious Freedom, an independent, bipartisan legislative branch agency that globally monitors the universal right to freedom of religion or belief.

As the 2026 academic year wrapped up, 99 Cornell employees celebrated completing their degrees while balancing the demands of full-time work.

Prostate-targeted, engineered nanoparticles made of amorphous silica are effective in killing prostate tumors directly while enhancing anti-tumor immunity, according to a preclinical study led by investigators at Weill Cornell Medicine and the Cornell Duffield College of Engineering. 

Dr. Dan Landau has received a Lotus Award from the Pershing Square Foundation for research aimed at uncovering new immunotherapy targets in ovarian cancer.

A new single-protein analysis technique gives researchers an unprecedented ability to study proteins called scramblases, which have critical roles in biology. The development of the new technique, in a study led by investigators at Weill Cornell Medicine and Ruhr University Bochum in Germany, expands the toolkit available to cell biologists and biophysicists and could someday be useful in devising new strategies against multiple diseases.

A carefully designed metal-free carbon monoxide prodrug—an inactive compound that is converted into its active form in the body—may help prevent some of the deadliest forms of cancer from spreading, according to researchers at Weill Cornell Medicine.

The majority of national climate adaptation plans fail to fully integrate health needs or engage populations most at risk from climate change, found an international team of investigators led by Weill Cornell Medicine.

The eighth cohort of the Biomedical Innovation Challenge showcased its innovations and development plans during a lightning round of pitches and judges’ questions on June 4 in the Belfer Research Building.

A circuit that runs from the prefrontal cortex near the front of the brain to a deeper brain structure called the insular cortex appears to mediate the antidepressant effects of a newer form of transcranial magnetic stimulation (TMS), according to a study led by Weill Cornell Medicine investigators.

Extreme heat and cold are growing cardiovascular risks that can trigger heart attacks, strokes, heart failure and sudden cardiac death, according to a recent scientific statement by experts at Weill Cornell Medicine and other leading institutions. 

The award recognizes exceptional investigators at Weill Cornell Medicine, The Rockefeller University and Memorial Sloan Kettering Cancer Center for their remarkable research achievements, impactful findings and high potential for success as independent investigators.

A new technology allows scientists to map, in single cells, the DNA binding sites of transcription factors and other regulatory proteins that control gene activity, according to a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

The ASCERTAIN V clinical trial, led by Weill Cornell Medicine researchers, demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment. 

Awards, honors and achievements for the month of May.